drugset / Trial / NCT07309042

Phase 1 Study of the Safety and Pharmacokinetics of YN001 With Rosuvastatin in Healthy Chinese Subjects

NCT07309042

Phase 1 Not yet recruiting 24 enrolled Beijing Inno Medicine Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of this study is to investigate the safety and tolerability of YN001 in combination with rosuvastatin, so as to provide evidence for the feasibility of YN001 combined with statins in subsequent clinical trials.

Timeline

Start
2025-12
Primary completion
2026-02
Completion
2026-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Rosuvastatin Small molecule 10 mg Oral
Subject YN001 Unknown 40 mg Intravenous